Thr453
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr453  -  LISCH (human)

Site Information
PsRGPALtPIRDEEW   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4771551
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 , 14 )
Disease tissue studied:
breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 2 ) , lung cancer ( 4 , 5 , 6 , 7 , 8 , 9 ) , non-small cell lung cancer ( 5 , 6 , 8 , 9 , 11 ) , non-small cell lung adenocarcinoma ( 5 , 6 , 7 , 8 , 9 , 11 ) , non-small cell large cell lung carcinoma ( 5 , 8 ) , non-small cell squamous cell lung carcinoma ( 7 ) , small-cell lung cancer ( 4 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 14 ) , breast ( 1 , 2 ) , Cal-12T (pulmonary) ( 9 ) , Calu-3 (pulmonary) ( 6 ) , DMS53 (pulmonary) ( 4 ) , Flp-In T-Rex-293 (epithelial) ( 13 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 13 ) , HCC15 (pulmonary) ( 7 ) , HCC44 (pulmonary) ( 9 ) , HCC78 (pulmonary) ( 8 ) , HCC827 (pulmonary) ( 6 ) , HeLa (cervical) ( 12 ) , K562 (erythroid) ( 12 ) , liver ( 3 ) , LOU-NH91 (squamous) ( 7 ) , lung ( 4 , 5 , 6 , 7 , 8 , 9 ) , NCI-H1299 (pulmonary) ( 5 ) , NCI-H1437 (pulmonary) ( 9 ) , NCI-H1650 (pulmonary) ( 6 ) , NCI-H1666 (pulmonary) ( 9 ) , NCI-H1703 (squamous) ( 7 ) , NCI-H1734 (pulmonary) ( 5 ) , NCI-H1781 (pulmonary) ( 8 ) , NCI-H1944 (pulmonary) ( 5 ) , NCI-H1975 (pulmonary) ( 6 ) , NCI-H2073 (pulmonary) ( 7 ) , NCI-H2106 (pulmonary) ( 6 ) , NCI-H2228 (pulmonary) ( 8 , 11 ) , NCI-H2342 (pulmonary) ( 7 ) , NCI-H2405 (pulmonary) ( 9 ) , NCI-H3122 (pulmonary) ( 8 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H446 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 5 ) , NCI-H526 (pulmonary) ( 4 ) , NCI-H661 (pulmonary) ( 8 ) , NCI-H69 (pulmonary) ( 4 ) , NCI-H82 (pulmonary) ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

11

Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

12

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

13

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

14

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info